• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
6-Methyl flavone inhibits Nogo-B expression and improves high fructose diet-induced liver injury in mice.6-甲基黄酮抑制 Nogo-B 表达并改善高果糖饮食诱导的小鼠肝损伤。
Acta Pharmacol Sin. 2023 Nov;44(11):2216-2229. doi: 10.1038/s41401-023-01121-7. Epub 2023 Jul 4.
2
Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity.Nogo 表达减少通过调节 ChREBP 和胰岛素活性抑制饮食诱导的代谢紊乱。
J Hepatol. 2020 Dec;73(6):1482-1495. doi: 10.1016/j.jhep.2020.07.034. Epub 2020 Jul 29.
3
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction.酮己糖激酶的药理学抑制可预防果糖诱导的代谢功能障碍。
Mol Metab. 2021 Jun;48:101196. doi: 10.1016/j.molmet.2021.101196. Epub 2021 Mar 3.
4
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease.膳食果糖与肝脏从头脂肪生成在脂肪肝疾病中的作用
Dig Dis Sci. 2016 May;61(5):1282-93. doi: 10.1007/s10620-016-4054-0. Epub 2016 Feb 8.
5
Fructose as a key player in the development of fatty liver disease.果糖在脂肪性肝病的发生发展中扮演关键角色。
World J Gastroenterol. 2013 Feb 28;19(8):1166-72. doi: 10.3748/wjg.v19.i8.1166.
6
Alleviates Non-Alcoholic Fatty Liver by Balancing Lipogenesis and Fatty Acid Oxidation in a High-Fat, High-Fructose Diet Mice Model.高脂高果糖饮食诱导的非酒精性脂肪肝病小鼠模型中通过脂生成和脂肪酸氧化的平衡缓解非酒精性脂肪肝病。
Cells. 2021 Dec 22;11(1):23. doi: 10.3390/cells11010023.
7
Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.肝细胞中的 Tcf7l2 调控饮食诱导的非酒精性脂肪性肝病小鼠模型中的从头脂肪生成。
Diabetologia. 2023 May;66(5):931-954. doi: 10.1007/s00125-023-05878-8. Epub 2023 Feb 10.
8
Fructose Mediated Non-Alcoholic Fatty Liver Is Attenuated by HO-1-SIRT1 Module in Murine Hepatocytes and Mice Fed a High Fructose Diet.HO-1-SIRT1模块可减轻果糖介导的非酒精性脂肪肝,该研究以喂食高果糖饮食的小鼠肝细胞和小鼠为对象
PLoS One. 2015 Jun 22;10(6):e0128648. doi: 10.1371/journal.pone.0128648. eCollection 2015.
9
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism.ChREBP 介导的 FGF21 分泌在肝脏果糖代谢中的关键作用。
Mol Metab. 2016 Nov 23;6(1):14-21. doi: 10.1016/j.molmet.2016.11.008. eCollection 2017 Jan.
10
6-Gingerol Inhibits De Novo Lipogenesis by Targeting Stearoyl-CoA Desaturase to Alleviate Fructose-Induced Hepatic Steatosis.6-姜酚通过靶向硬脂酰辅酶 A 去饱和酶抑制从头脂肪生成,从而减轻果糖诱导的肝脂肪变性。
Int J Mol Sci. 2024 Oct 20;25(20):11289. doi: 10.3390/ijms252011289.

引用本文的文献

1
Identification of Nogo-B as a potential therapeutic target of osteosarcoma via stereochemically selective covalent probes.通过立体化学选择性共价探针鉴定Nogo-B作为骨肉瘤的潜在治疗靶点。
Cell Death Dis. 2025 Jul 19;16(1):537. doi: 10.1038/s41419-025-07765-z.
2
Protective effects of Nogo-B deficiency in NAFLD mice and its multiomics analysis of gut microbiology and metabolism.Nogo-B缺乏对非酒精性脂肪性肝病(NAFLD)小鼠的保护作用及其肠道微生物群和代谢的多组学分析
Genes Nutr. 2024 Aug 24;19(1):17. doi: 10.1186/s12263-024-00754-5.
3
The role of AMPKα subunit in Alzheimer's disease: In-depth analysis and future prospects.AMPKα亚基在阿尔茨海默病中的作用:深入分析与未来展望。
Heliyon. 2024 Jul 6;10(13):e34254. doi: 10.1016/j.heliyon.2024.e34254. eCollection 2024 Jul 15.
4
Nogo-B Silencing Expedites the Senescence of Platelet-Derived Growth Factor-BB-Induced Human Hepatic Stellate Cells Via Autophagy.沉默Nogo-B通过自噬加速血小板衍生生长因子-BB诱导的人肝星状细胞衰老。
Mol Biotechnol. 2025 May;67(5):2023-2034. doi: 10.1007/s12033-024-01179-6. Epub 2024 May 10.
5
Inhibition of Nogo-B reduces the progression of pancreatic cancer by regulation NF-κB/GLUT1 and SREBP1 pathways.抑制Nogo-B可通过调节NF-κB/GLUT1和SREBP1信号通路来减缓胰腺癌的进展。
iScience. 2024 Apr 12;27(5):109741. doi: 10.1016/j.isci.2024.109741. eCollection 2024 May 17.

本文引用的文献

1
Mitochondria-targeted anti-oxidant AntiOxCIN improved liver steatosis in Western diet-fed mice by preventing lipid accumulation due to upregulation of fatty acid oxidation, quality control mechanism and antioxidant defense systems.线粒体靶向抗氧化剂AntiOxCIN通过上调脂肪酸氧化、质量控制机制和抗氧化防御系统来防止脂质积累,从而改善了西式饮食喂养小鼠的肝脏脂肪变性。
Redox Biol. 2022 Sep;55:102400. doi: 10.1016/j.redox.2022.102400. Epub 2022 Jul 16.
2
A marine-derived small molecule induces immunogenic cell death against triple-negative breast cancer through ER stress-CHOP pathway.一种海洋来源的小分子通过内质网应激-CHOP 通路诱导三阴性乳腺癌的免疫原性细胞死亡。
Int J Biol Sci. 2022 Apr 11;18(7):2898-2913. doi: 10.7150/ijbs.70975. eCollection 2022.
3
Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis.在非酒精性脂肪性肝炎饮食小鼠模型中,甲状腺激素可减轻肝脏脂肪变性、炎症和纤维化。
Thyroid. 2022 Jun;32(6):725-738. doi: 10.1089/thy.2021.0621. Epub 2022 May 25.
4
PHLPP1 promotes neutral lipid accumulation through AMPK/ChREBP-dependent lipid uptake and fatty acid synthesis pathways.PHLPP1通过AMPK/ChREBP依赖的脂质摄取和脂肪酸合成途径促进中性脂质积累。
iScience. 2022 Jan 12;25(2):103766. doi: 10.1016/j.isci.2022.103766. eCollection 2022 Feb 18.
5
Therapeutic regulation of autophagy in hepatic metabolism.肝脏代谢中自噬的治疗性调节
Acta Pharm Sin B. 2022 Jan;12(1):33-49. doi: 10.1016/j.apsb.2021.07.021. Epub 2021 Jul 28.
6
Inhibition of high-fat diet-induced obesity via reduction of ER-resident protein Nogo occurs through multiple mechanisms.通过减少内质网驻留蛋白 Nogo,可抑制高脂肪饮食诱导的肥胖,其机制多样。
J Biol Chem. 2022 Feb;298(2):101561. doi: 10.1016/j.jbc.2022.101561. Epub 2022 Jan 5.
7
The antihypertensive potential of flavonoids from Chinese Herbal Medicine: A review.中草药黄酮类化合物的降压作用:综述。
Pharmacol Res. 2021 Dec;174:105919. doi: 10.1016/j.phrs.2021.105919. Epub 2021 Oct 1.
8
The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights.果糖在非酒精性脂肪性肝炎中的作用:旧关系和新见解。
Nutrients. 2021 Apr 16;13(4):1314. doi: 10.3390/nu13041314.
9
Hyperoside relieves particulate matter-induced lung injury by inhibiting AMPK/mTOR-mediated autophagy deregulation.金丝桃苷通过抑制 AMPK/mTOR 介导的自噬失调缓解颗粒物诱导的肺损伤。
Pharmacol Res. 2021 May;167:105561. doi: 10.1016/j.phrs.2021.105561. Epub 2021 Mar 15.
10
Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?理解非酒精性脂肪性肝病发病机制中的脂毒性:CD36 是关键驱动因素吗?
Cell Death Dis. 2020 Sep 25;11(9):802. doi: 10.1038/s41419-020-03003-w.

6-甲基黄酮抑制 Nogo-B 表达并改善高果糖饮食诱导的小鼠肝损伤。

6-Methyl flavone inhibits Nogo-B expression and improves high fructose diet-induced liver injury in mice.

机构信息

Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, Hefei University of Technology, Hefei, 230031, China.

Department of Cardiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, China.

出版信息

Acta Pharmacol Sin. 2023 Nov;44(11):2216-2229. doi: 10.1038/s41401-023-01121-7. Epub 2023 Jul 4.

DOI:10.1038/s41401-023-01121-7
PMID:37402997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10618526/
Abstract

Excessive fructose consumption increases hepatic de novo lipogenesis, resulting in cellular stress, inflammation and liver injury. Nogo-B is a resident protein of the endoplasmic reticulum that regulates its structure and function. Hepatic Nogo-B is a key protein in glycolipid metabolism, and inhibition of Nogo-B has protective effects against metabolic syndrome, thus small molecules that inhibit Nogo-B have therapeutic benefits for glycolipid metabolism disorders. In this study we tested 14 flavones/isoflavones in hepatocytes using dual luciferase reporter system based on the Nogo-B transcriptional response system, and found that 6-methyl flavone (6-MF) exerted the strongest inhibition on Nogo-B expression in hepatocytes with an IC value of 15.85 μM. Administration of 6-MF (50 mg· kg ·d, i.g. for 3 weeks) significantly improved insulin resistance along with ameliorated liver injury and hypertriglyceridemia in high fructose diet-fed mice. In HepG2 cells cultured in a media containing an FA-fructose mixture, 6-MF (15 μM) significantly inhibited lipid synthesis, oxidative stress and inflammatory responses. Furthermore, we revealed that 6-MF inhibited Nogo-B/ChREBP-mediated fatty acid synthesis and reduced lipid accumulation in hepatocytes by restoring cellular autophagy and promoting fatty acid oxidation via the AMPKα-mTOR pathway. Thus, 6-MF may serve as a potential Nogo-B inhibitor to treat metabolic syndrome caused by glycolipid metabolism dysregulation.

摘要

过量的果糖摄入会增加肝脏从头合成脂肪,导致细胞应激、炎症和肝损伤。Nogo-B 是内质网的固有蛋白,调节内质网的结构和功能。肝 Nogo-B 是糖脂代谢的关键蛋白,抑制 Nogo-B 对代谢综合征具有保护作用,因此抑制 Nogo-B 的小分子对糖脂代谢紊乱具有治疗益处。在这项研究中,我们使用基于 Nogo-B 转录反应系统的双荧光素酶报告系统在肝细胞中测试了 14 种类黄酮/异黄酮,发现 6-甲基黄酮(6-MF)对肝细胞中 Nogo-B 表达的抑制作用最强,IC 值为 15.85 μM。6-MF(50mg·kg·d,ig,3 周)给药可显著改善胰岛素抵抗,改善高果糖饮食喂养小鼠的肝损伤和高甘油三酯血症。在含有 FA-果糖混合物的培养基中培养的 HepG2 细胞中,6-MF(15μM)显著抑制脂质合成、氧化应激和炎症反应。此外,我们发现 6-MF 通过恢复细胞自噬和通过 AMPKα-mTOR 通路促进脂肪酸氧化来抑制 Nogo-B/ChREBP 介导的脂肪酸合成和减少肝细胞中的脂质积累。因此,6-MF 可能作为一种潜在的 Nogo-B 抑制剂,用于治疗由糖脂代谢失调引起的代谢综合征。